Progentos Therapeutics Appoints Andrew Miller, Ph.D. to Chairman of its Board of Directors
Progentos Therapeutics, a biotech company addressing the critical unmet need to regenerate myelin and restore function for patients with Multiple Sclerosis (MS) and other demyelinating diseases, today ...
'It raises hope': A new drug for schizophrenia approved for the first time in 70 years
The Food and Drug Administration in the US has just approved Cobenfy, which one researcher referred to as a "game changer" ...
BioWorld13h
Kent Imaging looking to raise $25M for wound care devices
Kent Imaging Inc. is looking to raise $25 million in a series B financing round to expand the use of its imaging device for measuring wound and tissue oxygenation, and to support the launch of a new ...
BioWorld14h
US strike, hurricane threaten global drug, device supply chain
Depending on how long it lasts, the dockworkers strike that hit all 14 ports on the U.S. East Coast and along the Gulf Oct. 1 could literally unload a world of hurt to patients and the ...
BioSpace20h
The Making of BMS’ Cobenfy: From Alzheimer’s to Schizophrenia
From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...
biopharma-reporter22h
BMS achieves FDA approval for schizophrenia drug Cobenfy
Bristol Myers Squibb (BMS) acquired Karuna Therapeutics, the developer of KarXT, in a deal worth US $14.0 billion in equity ...